A long thread on snakebite- a neglected public health problem in India.
1/N India has the highest number of deaths due to #snakebites in the world. Snakes bite, injure, or disable hundreds of thousands of people and kill close to 58 000 Indians each year.
2/N Victims of snakebite often need ICU admission and access to ventilators and dialysis. Venomous snakebite is more expensive to treat than treating a heart attack or a stroke.
3/N People living in villages are at risk of snakebite because their housing conditions are poor and inadequate lighting makes it easy for the snakes to access their living spaces. Open-style habitation, open defecation and the sleeping on the floor often expose people to bites.
4/N Snakebites are often associated with failure of vital organs and most rural hospitals lack the intensive care facilities required for the care of patients with multi-organ dysfunction. Antivenom is expensive (Rs 5000-10 000), and its inappropriate use in hospitals is common.
5/N The “big 4” venomous snakes in India are common cobra (Naja naja), Russell's viper (Dabiola russelii), saw-scaled viper (Echis carinatus) & common krait (Bungarus caeruleus).
The snake venom is a cocktail of enzymes, polypeptides, glycoproteins; 90% snake venom is protein.
6/N Snake venoms predominantly cause paralysis (Cobras and Kraits) or do not allow the blood to clot (Vipers).
7/N Patients come to hospitals with:
“Dry bite” (a venomous snake bites a person & the victim does not suffer from any signs or symptoms of envenomation), or bite by a non-venomous snake. 50% bites by Russell’s vipers, 30% by cobras, and 10% by saw-scaled vipers are dry bites.
8/N Local envenoming: Fang marks, local pain (burning, bursting, throbbing), swelling that extends up the limb, enlarged and tender lymph nodes draining the site of the bite, blistering, necrosis and local bleeding. Krait bites are typically painless.
10/N Neurological (Cobra and Krait): Droopy eyes usually within a few hours of the bite. Double vision, difficulty breathing, difficulty swallowing and respiratory muscle weakness follows. A few patients require mechanical ventilation, often for weeks
11/N EARLY CLUES THAT A PATIENT HAS SEVERE ENVENOMING
●Rapid early extension of local swelling from the site of the bite
●Early tender enlargement of local lymph nodes
●Early systemic symptoms:
oLow BP
oVomiting
oHeavy eyelids, Droopy eyes,
oNose bleed, gum bleeding
12/N The 20-min whole blood clotting test, a cheap and simple test, is the most commonly used test to quickly diagnose venomous snakebite and administer antivenom.
13/N A few milliliters of blood is placed in a new, dry glass test tube. After 20 minutes, the tube is tipped to assess if a clot has formed. The test is negative if a clot is formed and positive if the blood is still liquid and unclotted.
14/N ANTIVENOM TREATMENT
Antivenoms are often unavailable or unaffordable for the poor, rural people most likely to be bitten. Most PHCs either do not stock enough antivenom or administer only a tenth of the full dose—a common practice.
15/N ANTIVENOM: DO’S AND DON’TS
●Use ASV only when its benefits exceed the adverse effects.
●Avoid inappropriate use of ASV.
●Do not use skin tests to predict ASV reactions.
●Ensure that epinephrine is available at the bedside before ASV is administered.
16/N ANTIVENOM: DO’S AND DON’TS
Do not administer ASV locally and by intramuscular route.
●Observe patients for at least one hour after injecting ASV.
●Children should receive exactly the same dose of ASV as adults.
●Do not rely on ASV alone to treat Krait bite.
17/N WHEN ANTIVENOM TREATMENT?
Antivenom should be administered as soon as possible as it is effective only against freely circulating venom.
Inject Antivenom whenever there are signs of systemic envenomation or presence of severe local swelling.
18/N When should we inject anti snake venom?
19/N DOSAGE OF ANTIVENOM
The response to antivenom is highly dependent on the toxins of the biting snake and the severity of envenoming. In practice, initial dose is often chosen empirically.
Patients with Cobra, Viper or Krait envenoming requires 100-200 ml. (10-20 vials).
20/N How do we know that antivenom has worked?
If after antivenom infusion (1) blood pressure becomes normal, (2) bleeding stops, (3) blood begins to clot again and (4) nerves begin to function normally.
Antivenom may not reverse respiratory muscle paralysis caused by Kraits.
21/N When do we repeat the antivenom?
1.Blood has not clotted — on a bedside 20-minute blood clotting test—after 6 hours of the first dose of antivenom.
2. Heart and nervous system dysfunction after 1 hour of antivenom.
22/N How do we prevent antivenom reactions?
0.25 mg adrenaline given subcutaneously before ASV administration is safe and reduces the risk of acute severe reactions to ASV.
Anti-histamines and steroids are ineffective for this purpose.
23/N Cobra differs from Krait!
Cobra: Improvement in paralytic signs may become clinically evident within 30–60 minutes of an initial dose of 10 vials of antivenom.
Krait: No evidence to justify the prolonged administration of antivenom in paralyzed and ventilated patients.
24/N ACUTE KIDNEY INJURY
A fifth of patients develop acute kidney injury following a venomous snakebite. Cautious intravenous fluids, diuretics, and haemodialysis or peritoneal dialysis may be required in acute kidney injury.
25/N Sleeping under a mosquito net and on a bed above ground level, keeping domestic areas free of rubbish, rubble, and firewood and controlling rodent populations are vital to prevent deaths from snakebites.
Two wishes. (1) Can Indian scientists develop point of care molecular tests to help care providers identify the species responsible for snakebites? Accurately, quickly and cheaply?
Can Government develop monovalent antisnake venom for the big four (Russell’s and Saw-scaled Viper, Cobra and Krait) to improve the efficacy of antivenom? And ensure its adequate availability?
Thousands of lives can be saved if we achieve these two goals. #SaveLives#snakebite
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/n My 7-slide summary of the @NEJM 7 July study on safety and effectivity of #COVID19Vaccination in adolescents
Q What was the research question?
Is Covid vaccine safe and effective in adolescents aged 12-15 years of age?
2/n What did the researchers do?
In an ongoing multinational, placebo-controlled, observer-blinded trial, researchers randomly assigned 2260 adolescents to receive two injections, 21 days apart, of BNT162b2 vaccine or placebo.
3/n Was the vaccine safe, immunogenic and effective?
Yes
Yes
Yes
1/n The COLCORONA clinical trial (Lancet 27 May 2021) concludes that if we treat 70 Covid positive people with colchicine for a month, we prevent 1 hospital admission or death.
How did the researchers estimate the sample size of their study?
2/n Assumptions. They assumed that 7% of those on placebo shall either die or need hospital admission. Oral colchicine shall reduce this number to 5.25.
To detect a difference between the 2 arms of the study, they needed to enrol about 6000 people in the study. Which they did.
3/n The outcome in the colchicine trial was death or hospital admission. The secondary outcome was the need for mechanical ventilation.
Outcomes that are clinically meaningful. Outcomes that matter most to patients or their family.
I cringe when Times of India reports results from a COVID19 case-series from Maharashtra- drugs are doing great. Not a word on control arm or standard of care. They should ask—and tell us—who did they compare the drug with. These numbers are confusing and distort science. 1/4
First, #Favipiravir. Maharashtra reports that 5.5% (27/495) mildly sick COVID patients on Favipiravir died. Normally, about 98% of such patients recover. Are these results “encouraging”? Or should we be worried about the association of increased mortality with Favipiravir? 2/4
Second, #Remdesivir. The NEJM RCT showed that 7.1% on Remdesivir died compared to 11.9 % on placebo. The results lacked statistical significance. In Maharashtra, 29% (89/311) patients receiving Remdesivir died. Should we call these results promising? 3/4
My quick comments on the #Favipiravir study results released by #GLENMARK in a press release.
Did Favipiravir succeed in achieving faster viral clearance? No. The difference between the two arms of the study lacks statistical significance. The 95% CIs cross 1. N/1
What about secondary endpoints? Would you pay Rs 12500 for a drug that promises to make you fever-free a day earlier?
Look at the 95% CIs again- they barely float above 1! Not impressive! And were these patients hypoxic? The data does not tell us. 2/2
#Favipiravir group tended to require oxygen late compared to the usual care group.
OK. The trouble is, we do not know, eventually how many required oxygen in each group. 95% Cis touch 1- meaning no difference between the two groups. 3/4